Search - tctmd.com

Displaying 221 - 240 of 764

Sort: Relevancy | Date

News Conference News ISET 2019

Paclitaxel in PAD: What to Tell Patients While the Numbers Are Crunched

Caitlin E. Cox

January 28, 2019

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

News Daily News

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

L.A. McKeown

January 23, 2019

News Daily News

FDA Alerts Doctors to Potential Late Risks With Paclitaxel-Coated Balloons and Stents in PAD

Michael O'Riordan

January 17, 2019

Presentation

Frequency of TVR With DCB vs Second-Generation DES for Coronary In-Stent Restenosis

January 15, 2019

News Daily News

Slight Advantage for DES Over DCB for In-Stent Restenosis: Updated Meta-analysis

Todd Neale

January 15, 2019

News Daily News

Guidelines for Peripheral Interventions Often Built on Shaky Foundation

Caitlin E. Cox

January 10, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for December 2018

Caitlin E. Cox

January 01, 2019

News Daily News

The Biggest News of 2018: TCTMD’s Top 10

Shelley Wood

December 31, 2018

News Features

Top News in Endovascular Therapy: 2018

L.A. McKeown

December 28, 2018

News Daily News

Two Trials Halted in Wake of Study Linking Paclitaxel-Coated Devices to Deaths in PAD

L.A. McKeown

December 17, 2018

News Daily News

Signal of Late Deaths With Paclitaxel-Coated DCBs and Stents for PAD Warrants Urgent Review, Authors Say

L.A. McKeown

December 07, 2018

News Conference News VIVA 2018

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

L.A. McKeown

November 13, 2018

News Conference News VIVA 2018

LUTONIX BTK: Hope for Challenging Patients at High Risk for Amputation

L.A. McKeown

November 07, 2018

News Conference News VIVA 2018

IMPERIAL Substudy Provides Reassurance for Benefit of Eluvia in Long Lesions

L.A. McKeown

November 06, 2018

Presentation TCT Abstracts Posters 2018

Comparison of midterm outcome between small and non-small vessel after paclitaxel coated balloon treatment in de novo native coronary artery disease

Presenter: Ritsu Yoshida

September 25, 2018

Presentation TCT Abstracts Posters 2018

Comparison of the Outcomes with or without Excimer Laser Coronary Angioplasty for the Treatment of Coronary In-Stent Restenosis using Paclitaxel-Coated Balloon

Presenter: Motoyoshi Maenaka

September 25, 2018

Presentation TCT Abstracts Posters 2018

Comparison of the Outcomes with or without Excimer Laser Coronary Angioplasty for the Treatment of Coronary In-Stent Restenosis using Paclitaxel-Coated Balloon

Presenter: Motoyoshi Maenaka

September 25, 2018

News Conference News TCT 2018

Eluvia Gains FDA Approval Just Days After IMPERIAL Results Released

Todd Neale

September 24, 2018

News Conference News TCT 2018

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

Todd Neale

September 22, 2018

Advertisement

Paclitaxel in PAD: What to Tell Patients While the Numbers Are Crunched

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

FDA Alerts Doctors to Potential Late Risks With Paclitaxel-Coated Balloons and Stents in PAD

Frequency of TVR With DCB vs Second-Generation DES for Coronary In-Stent Restenosis

Slight Advantage for DES Over DCB for In-Stent Restenosis: Updated Meta-analysis

Guidelines for Peripheral Interventions Often Built on Shaky Foundation

TCTMD’s Top 10 Most Popular Stories for December 2018

The Biggest News of 2018: TCTMD’s Top 10

Top News in Endovascular Therapy: 2018

Two Trials Halted in Wake of Study Linking Paclitaxel-Coated Devices to Deaths in PAD

Signal of Late Deaths With Paclitaxel-Coated DCBs and Stents for PAD Warrants Urgent Review, Authors Say

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

LUTONIX BTK: Hope for Challenging Patients at High Risk for Amputation

IMPERIAL Substudy Provides Reassurance for Benefit of Eluvia in Long Lesions

Comparison of midterm outcome between small and non-small vessel after paclitaxel coated balloon treatment in de novo native coronary artery disease

Comparison of the Outcomes with or without Excimer Laser Coronary Angioplasty for the Treatment of Coronary In-Stent Restenosis using Paclitaxel-Coated Balloon

Comparison of the Outcomes with or without Excimer Laser Coronary Angioplasty for the Treatment of Coronary In-Stent Restenosis using Paclitaxel-Coated Balloon

Eluvia Gains FDA Approval Just Days After IMPERIAL Results Released

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content